Literature DB >> 2892291

Facilitation of allogeneic bone marrow transplantation by a T cell-specific immunotoxin containing daunomycin.

S S Xie1, M Inazawa, N Sinha, S Sawada, R Vergidis, E Diener.   

Abstract

Daunomycin coupled via an acid-sensitive spacer to monoclonal Thy-1.2-specific antibody was used to purge T lymphocytes from a 1:1 mixture of murine C57BL/6J bone marrow and spleen cells prior to engraftment in fully allogeneic, irradiated BALB/c recipients. Treatment of bone marrow with the immunotoxin at a concentration used for purging had no effect on the viability of committed hematopoietic progenitor or multipotent stem cells. All of the recipients of purged bone marrow were at least 80% chimeric for donor peripheral blood cells and none developed graft-versus-host disease. Out of 50 chimeras, 49 were still alive more than 200 days posttransplantation. The chimeras were shown to be tolerant to donor tissue as tested by mixed lymphocyte reactivity, cell-mediated cytotoxicity, and skin grafting. The same tests revealed full immunocompetence of chimeras to third-party alloantigens. In vivo IgM and IgG antibody responses to sheep red blood cells were similar in magnitude in allogeneically and syngeneically reconstituted mice.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892291     DOI: 10.1097/00007890-198712000-00009

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  1 in total

1.  Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas.

Authors:  L Ding; J Samuel; G D MacLean; A A Noujaim; E Diener; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.